NATIONAL COMPREHENSIVE CANCER NETWORK
Updated 192 days ago
POLIVY in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater...
NCCN recommends polatuzumab vedotin-piiq (POLIVY) + R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) as a category 1 preferred treatment option for patients with previously untreated stage II (with extensive mesenteric disease) or stage III-IV diffuse large B-cell lymphoma and IPI score ≥2.2,*...
*NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
Also known as: National Comprehensive Cancer Network, Inc, NCCN